Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06465329 · ClinicalTrials.gov registry record · Phase 2
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT06465329 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 120 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06465329, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug. The study is also looking at several other research questions, including: * What are the side effects associated with the investigational treatments in comparison to the control treatment? * Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed? * How much of the study drug(s) are in the blood at a given time? * Does the body make antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects)?
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG Platinum-based chemotherapy
- DRUG REGN7075
Study Locations (20)
Tennessee
- University of Tennessee Medical Center - Knoxville
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Nashville
- Tennessee Oncology - Nashville
Michigan
- Karmanos Cancer Institute - Detroit
- Detroit Clinical Research Center - Farmington Hills
New Jersey
- Morristown Medical Center - Morristown
- Rutgers Cancer Institute of New Jersey - New Brunswick
Oregon
- Providence Portland Medical Center - Portland
- University Of Nebraska Medical Center - Portland
Minas Gerais
- Instituto Mario Penna - Belo Horizonte
- Instituto Sul Mineiro De Oncologia LTDA - Pouso Alegre
California
- University of California Irvine - Orange
Illinois
- Orchard Healthcare Research Inc. - Skokie
Rhode Island
- Lifespan Cancer Institute - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2030-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06465329
The ClinicalTrials.gov registry entry for NCT06465329 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cemiplimab is the first listed.
NCT06465329 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Tennessee, Michigan, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06465329 about?
NCT06465329 is a clinical study titled "A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)". This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemi...
What is the current status of trial NCT06465329?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-11-18. Estimated completion is 2030-05-02.
What conditions does trial NCT06465329 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06465329?
The interventions under investigation include: Cemiplimab (DRUG), Platinum-based chemotherapy (DRUG), REGN7075 (DRUG).
Who is sponsoring clinical trial NCT06465329?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06465329 being conducted?
This trial has 20 study locations across California, Illinois, Michigan, New Jersey, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.